Brief: CEL-SCI Gets FDA Go-Ahead For Study Of Multikine In Treatment Of Head, Neck Cancer
Brief: Cel-Sci Announces Closing Of $5 Million Public Offering Of Common Stock
Brief: Cel-Sci Announces Pricing Of $5 Million Offering Of Common Stock
Brief: 5-Year Head & Neck Cancer Survival Increased From 45% To 73% In CEL-SCI’s Target Population
Brief: Cel-Sci Files Request With The UK's MHRA Regarding Path To Approval For Multikine In The Treatment Of Head & Neck Cancer
CEL-SCI tumbles on deep-discounted stock offering
Brief: Cel-Sci Announces Pricing Of Public Offering
Brief: CEL-SCI Announces Proposed Public Offering Of Common Stock
Brief: CEL-SCI Reports Phase 3 Tumor PD-L1 Biomarker Data
Brief: Histopathology And Tumor Biomarker Analysis Confirm Cel-Sci's Multikine Significantly Prolonged Overall Survival In Head & Neck Cancer—Phase 3 Data Presented At ESTRO 2023
Brief: Cel-Sci Corporation Reports Second Quarter Fiscal 2023 Financial Results
Brief: Cel-Sci Announces $1.35 Million Underwritten Confidentially Marketed Public Offering Of Common Stock
Brief: CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension
Brief: CEL-SCI Corp Posts Qtrly Loss Per Share $0.18
Celsius' business model different from that advertised -U.S. bankruptcy examiner (updated)
Brief: Cel-Sci Corp - Phase 3 Trial Showed Multikine Immunotherapy Extended Lives Of Patients With Locally Advanced Primary Scchn - Oral Cavity/Soft Palate
Brief: Cel-Sci’S Announces Phase 3 Study Results
Brief: CEL-SCI Presents Phase 3 Data At ESMO 2022
Brief: CEL-SCI Corporation announces Phase 3 Multikine® head and neck cancer results posted on clinicaltrials.gov